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Abstract
The class II trans-activator CIITA is a transcriptional co-activator required for the expression of Major Histocompatibility
Complex (MHC) genes. Although the latter function is well established, the global target-gene specificity of CIITA had not
been defined. We therefore generated a comprehensive list of its target genes by performing genome-wide scans
employing four different approaches designed to identify promoters that are occupied by CIITA in two key antigen
presenting cells, B cells and dendritic cells. Surprisingly, in addition to MHC genes, only nine new targets were identified and
validated by extensive functional and expression analysis. Seven of these genes are known or likely to function in processes
contributing to MHC-mediated antigen presentation. The remaining two are of unknown function. CIITA is thus uniquely
dedicated for genes implicated in antigen presentation. The finding that CIITA regulates such a highly focused gene
expression module sets it apart from all other transcription factors, for which large-scale binding-site mapping has indicated
that they exert pleiotropic functions and regulate large numbers of genes.
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Introduction
Most mammalian transcription factors are believed to activate
numerous genes having diverse functions. Direct support for this
pleiotropic nature of transcription factor function has been
provided by techniques permitting the unbiased mapping of
transcription factor binding sites in substantial segments of
genomic DNA, whole chromosomes or entire genomes. These
large scale location techniques rely on sequencing or microarray
(chip) analysis of genomic DNA sequences that are enriched by
chromatin immunoprecipitation (ChIP) experiments. To date, all
transcription factors for which these methods have been applied
were found to bind to numerous target genes, typically in the order
of several hundred to several thousand per genome [1–5]. The
past few years has witnessed a controversy about whether this
general rule of pleiotropic function is also valid for the Major
Histocompatibility Complex class II (MHC-II) gene transactivator
CIITA (NM_000246).
CIITA was first established to be a key regulator of MHC-II
genes because it was found to be mutated in an in vitro generated B
cell line lacking MHC-II expression [6]. Mutations in the CIITA
gene were next shown to be one of the causes of the Bare
Lymphocyte Syndrome (BLS) (MIM number: 600005), a hered-
itary immunodeficiency disease characterized by the virtually
complete absence of MHC-II expression and a significant
reduction in MHC class I (MHC-I) expression [6,7]. In
accordance with these genetic findings, CIITA was subsequently
shown to be a non-DNA-binding transcriptional co-activator that
is essential for expression of the genes encoding the a and b chains
of all classical and non-classical MHC-II molecules (HLA-DR,
HLA-DP, HLA-DQ, HLA-DM, HLA-DO in humans) as well the
gene encoding the Invariant chain (Ii), an accessory molecule
controlling intracellular transport and peptide loading of MHC-II
molecules [7–9]. CIITA was also found to contribute, albeit to a
lesser extent, to the transcription of MHC-I genes [7–12].
All clinical and immunological abnormalities documented in
BLS patients can be explained by defects in MHC expression [7].
The same is true for knockout mice carrying mutations in the
CIITA gene [7,9]. The absence of other overt phenotypes
suggested that CIITA is highly dedicated for the transcription of
MHC genes. It therefore came as a major surprise when a growing
number of reports suggested that CIITA can affect the expression
of numerous genes involved in diverse functions within and outside
the immune system. Microarray experiments identified the gene
encoding Plexin-A1, which was reported to be activated by CIITA
in mouse DC [13], and over 40 genes that were suggested to be
up-regulated by CIITA in human B cells and interferon-c (IFNc)
induced cells [14]. The genes encoding IL-4 and Fas ligand were
proposed to be repressed by CIITA in mouse T cells [15–18].
Those encoding cathepsin E and IL-10 were suggested to be
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repressed by CIITA in mouse B cells and/or DC [19,20] . The
genes encoding collagen type I a2, tymidine kinase and cyclin D1
were proposed to be repressed by CIITA in IFNc induced cells
[21,22]. Finally, microarray experiments identified 16 genes of
diverse functions that were proposed to be down-regulated by
CIITA in human B cells [14]. Taken together, these reports
suggested that CIITA has widespread functions extending beyond
its well established role in the control of MHC expression.
The notion that CIITA exerts pleiotropic functions was at odds
with the highly specific defects observed in BLS patients and
CIITA-deficient mice. To address this discrepancy we set out to
define the complete set of CIITA target genes by performing
genome-scale ChIP-chip experiments. Our results demonstrate
that CIITA is remarkably dedicated for the regulation of genes
implicated in MHC-II and MHC-I mediated antigen presentation.
Outside of the well established MHC-II, MHC-I and Ii genes, only
nine new target genes were identified, seven of which are known or
likely to function in processes related to antigen presentation. The
finding that CIITA regulates such a highly specialized genetic
module sets it apart from all other transcription factors for which
large scale mapping of binding sites has been performed.
Results
Strategies for Identifying CIITA Target Genes
Approaches for identifying novel target genes of CIITA were
developed on the basis of its expression and mode of action
(Figure 1). The pattern of CIITA expression dictates the cell type
specificity of MHC-II expression (Figure 1A) [23]. B cells and
immature dendritic cells (iDC) are MHC-II positive because they
express CIITA. The CIITA gene is instead silenced in mature DC
(mDC) [24]. Most non-hematopoietic cells are MHC-II negative
because they lack CIITA. The latter can however be induced to
activate CIITA expression by stimulation with IFNc. CIITA is
recruited to its known target genes through protein-protein
interactions with a transcription factor complex that assembles
Author Summary
Most mammalian transcription factors and transcriptional
co-activators are believed to regulate the activities of
numerous genes fulfilling multiple functions. This pleio-
tropic role has recently been confirmed directly for several
individual factors by large-scale mapping studies aimed at
generating comprehensive catalogues of their binding
sites in the genome. Until now, all transcription factors, for
which such studies have been performed, were found to
regulate hundreds or even thousands of genes. We
demonstrate, here, that the transcriptional co-activator
CIITA (class II transactivator) is an exception to this rule.
CIITA is a key regulator of the immune system because it
controls the transcription of genes coding for Major
Histocompatibility Complex (MHC) class II molecules,
which are cell-surface molecules that present peptide
antigens to T lymphocytes. To address the possibility that
CIITA might exert more widespread functions, we have
performed extensive genome-wide searches to establish a
comprehensive list of CIITA-regulated genes. Surprisingly,
we found that CIITA regulates only a small number of
genes, most of which code for proteins implicated directly
or indirectly in MHC-mediated antigen presentation. CIITA
is thus remarkably dedicated for the regulation of a unique
set of functionally related genes constituting a genetic
module devoted to a single biological process.
Figure 1. ChIP-chip strategies used to identify target genes of
CIITA. (A) Schematic representation of the expression and function of
CIITA. Expression of the CIITA gene is regulated by three independent
promoters – pI, pIII and pIV – that are activated in iDC, B cells and IFNc
induced cells, respectively. pI is silenced after maturation of DC (mDC).
CIITA is a non-DNA-binding co-activator that activates expression of its
known target genes (MHC-II, MHC-I, Ii) by binding to a transcription
factor complex that assembles on an enhancer consisting of S, X, X2
and Y sequences. Known CIITA target genes contain an S-Y enhancer
typically situated less than 200 bp upstream of the transcription
initiation site. The X-box-binding factor RFX is essential for CIITA
recruitment. (B) Four ChIP-chip strategies were developed for
identifying target genes of CIITA in B cells and iDC. Test probes
generated from CIITA-ChIP samples obtained from Raji B cells and iDC
were hybridized to NimbleGen promoter arrays. Control probes were
prepared from input DNA or CIITA-ChIP samples derived from RJ2.2.5
cells, SJO cells or mDC. (C) Enrichment of known CIITA target sequences
in CIITA-ChIP probes. Quantitative PCR was used to verify enrichment of
the HLA-DRA promoter in the indicated test samples (black bars) relative
to control samples (open bars). The approximate fold-enrichment is
indicated. To estimate enrichment relative to input DNA we used a
control sequence exhibiting only nonspecific CIITA association (back-
ground). The results show the mean and SD of 3 independent
experiments (each performed with triplicate PCR measurements).
doi:10.1371/journal.pgen.1000058.g001
Remarkably Tight CIITA Target Gene Specificity
PLoS Genetics | www.plosgenetics.org 2 April 2008 | Volume 4 | Issue 4 | e1000058
on a characteristic enhancer composed of four sequences called
the S, X, X2 and Y boxes (Figure 1A) [7–9]. Regulatory factor X
(RFX) - a trimeric factor containing three subunits called RFX5
(NM_000449), RFXAP (NM_000538) and RFXANK
(NM_134440) - is an essential component of this transcription
factor complex [25–29]. CIITA recruitment is abolished in RFX-
deficient cells [30–33]. Like defects in CIITA, mutations in the
RFX5, RFXAP and RFXANK genes give rise to the BLS disease
(MIM number: 601863, 601861, 603200).
Based on the above, we devised genome-wide ChIP-chip
approaches according to four different experimental designs
(Figure 1B). In all four approaches, ChIP samples obtained with
CIITA-specific antibodies were used to prepare probes that were
hybridized in conjunction with control probes to microarrays
carrying the promoter regions of 27434 human genes. The four
strategies differed with respect to the cell type used to prepare the
ChIP samples and the control probes to which they were
compared. In the first strategy, CIITA-ChIP probes derived from
the wild type B cell line Raji were compared with CIITA-ChIP
probes derived from RJ2.2.5, a CIITA-deficient mutant of Raji. In
the second strategy, CIITA-ChIP samples prepared from iDC
were compared with CIITA-ChIP samples from mDC. In the
third strategy, CIITA-ChIP probes derived from Raji were
compared with input genomic DNA from Raji. In the fourth
stratetgy, CIITA-ChIP probes derived from Raji were compared
with CIITA-ChIP probes prepared from a cell line (SJO) derived
from an RFX5-deficient BLS patient. In all four experimental
settings, there is a robust enrichment of known CIITA target
sequences, such as the HLA-DRA promoter, in the test samples
relative to the control samples (Figure 1C).
Validation of the ChIP-Chip Screens
To validate our screening strategies we examined binding of
CIITA to the promoters of well established target genes, including
MHC-II, Ii and MHC-I genes (Figure 2, Table 1, Figure S1). Clear
binding of CIITA – visualized as peaks in the test/control signal
ratios - was observed in Raji B cells and iDC at positions
corresponding to the S-Y enhancers of these genes. Despite some
variability in the width and height of the peaks, binding of CIITA
at the correct position was observed reproducibly in nine
independent experiments using all four screening strategies.
Binding signals were strong; test/control signal ratios typically
ranged from a minimum of 6 to over 30 depending on the target
gene and the experiment. Binding of CIITA was never observed at
control genes that are not regulated by CIITA (Figure 2, Figure
S2). The sensitivity of our ChIP-chip approach was high. The
false-negative rate was only ,5% at well-established target genes
(Table 1). Furthermore, robust peaks were observed in all or most
experiments even at the HLA-DOB, HLA-DPB, HLA-DMB and
HLA-DQA genes (Table 1) despite the fact that CIITA binding
signals observed at these genes in classical ChIP experiments are
typically 10–20 fold lower than those observed at the prototypical
HLA-DRA gene [32].
Certain peaks exhibit a dip in CIITA binding at a position that
coincides with the S-Y enhancer (Figure 2). These dips are likely to
be artifacts because they generally concerned only a single
oligonucleotide on the array, were not observed in all experiments
and were not observed in experiments using high density
microarrays (see discussion).
Identification of New CIITA Target Genes
To identify potential new targets of CIITA, we developed a
procedure to screen for the presence of reproducible peaks in the
test/control signal ratios obtained in multiple Raji/RJ2.2.5 and
iDC/mDC comparisons (see Materials and Methods). Candidate
genes were assigned a score on the basis of peak height, width and
reproducibility. A score of 3 was assigned to the candidate genes at
which peak quality and reproducibility were similar to those
observed for known target genes (Table 1). A score of 2 was
assigned to candidate genes for which peak quality and/or
reproducibility were promising but significantly lower than for
known target genes (Table 1). Finally a score of 1 was assigned to
possible but unlikely candidates exhibiting only weak and poorly
reproducible peaks (Table S1). The number of likely candidates
was surprisingly low: scores of 3 and 2 were assigned, respectively,
to only twelve and twenty genes.
To validate bona fide new target genes we screened the most
promising candidates for binding of CIITA in Raji B cells by
quantitative ChIP experiments (Figure 3A). All twelve score 3
candidates, sixteen score 2 candidates and a selection of the best
score 1 candidates were tested. The primers used for real-time
PCR analysis of the ChIP experiments were designed within the
regions at which peaks were observed in the ChIP-chip
experiments. Four score 2 candidates were not tested because
suitable primers could not be designed. Binding of CIITA was
confirmed for eight score 3 candidates (RAB4B, TRIM26,
FLJ45422, KIAA0841, RFX5, ZNF672, TPP1 and MYBPC2) and
only one score 2 candidate (PSMD3). Weaker binding was
observed at two additional score 2 genes (BRD2 and TRIM14),
but these were not studied further because signals were only 2–3
fold above background. No significant binding was evident at the
remaining score 3 and score 2 genes, or at any of the tested score 1
genes (Figure 3, Table 1, Table S1). The finding that most of the
score 3 candidates, only one of the score 2 candidates and none of
the tested score 1 candidates are true targets of CIITA
demonstrates the validity of our scoring procedure. These results
also demonstrate that the specificity of our approach is greatest if
peak reproducibility is chosen as the most critical parameter for
predicting target genes (Table 1). Thus, among genes at which
peaks are present in at least four out of five experiments (MHC-II
and score 3 genes) less than 20% were found to be false positives,
whereas the false positive rate increased dramatically among genes
at which peaks were detected at only three out of five experiments
(score 2 genes).
Representative ChIP-chip profiles corresponding to binding of
CIITA in Raji are provided in Figure 3B for the nine validated
target genes. Peaks similar in quality to those found at theMHC-II,
MHC-I and Ii genes are observed near the transcription initiation
site of all nine genes (compare Figure 3B with Figure 2 and Figure
S1).
To further confirm the specificity of our quantitative ChIP
experiments we compared occupation of the new targets by
CIITA between Raji and its CIITA-deficient derivative RJ2.2.5.
As observed for the control HLA-DRA and Ii genes, binding of
CIITA is reduced to non-specific background levels in RJ2.2.5 at
all nine new target genes (Figure 3C).
To address the possibility that numerous true target genes might
have been missed by our data analysis procedure we used two
additional independent methods to analyze the same datasets.
First, the windowing and threshold program ACME (Algorithm
for Capturing Microarray Enrichment) [34] was used for peak
detection, and significant peaks present in at least four out of five
experiments were identified. In addition to MHC-II and related
genes, this procedure identified only 17 potential new target genes
(data not shown). Quantitative ChIP experiments performed with
11 of these showed that only 3 represented true CIITA targets
(RFX5, RAB4B, PSMD3). The other 8 were found to be false
positives that had been assigned scores of 3 (3 genes), 2 (2 genes)
Remarkably Tight CIITA Target Gene Specificity
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Figure 2. Binding of CIITA to known target genes. Binding of CIITA to the HLA-DRA, HLA-DRB1, HLA-DMA, HLA-DOA, Ii and HLA-C genes is
evident in the ChIP-chip experiments performed with Raji B cells and iDC. The RAB4A gene was used as negative control. Results are represented as
log2 ratios between hybridization signals obtained with CIITA-ChIP probes from Raji and RJ2.2.5 (left column) or iDC and mDC (right column). Each
dot corresponds to a single oligonucleotide on the array. The dotted line in the right HLA-C profile indicates a peak that was not reproduced in all
experiments. The schematic maps show positions of the transcription start sites (arrows) and S-Y enhancers (grey boxes). The scale in Kb relative to
the start site is provided below.
doi:10.1371/journal.pgen.1000058.g002
Remarkably Tight CIITA Target Gene Specificity
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and 1 (3 genes) by our initial procedure. The remaining 6
candidates were not tested because visual inspection of their ChIP-
chip peaks revealed that they were of very low quality and highly
likely to correspond to false positive hits. Importantly, 6 of the
validated new CIITA target genes (TRIM26, FLJ45422,
KIAA0841, ZNF672, TPP1 and MYBPC2) were not picked up.
As a second alternative approach we developed an unsupervised
clustering procedure (see Material and Methods). This method
grouped potential candidates into 8 groups on the basis of peak
reproducibility and log2 signal ratios (data not shown). The two
groups corresponding to the most likely targets contained only 12
and 29 genes respectively. 12 of these were MHC-II genes and 6
were among the new validated targets (RAB4B, TRIM26, KIAA0841,
RFX5, ZNF672 and MYBPC2). Among the remaining 23 genes, 2
were found to be false positives by ChIP experiments and 22 were
eliminated as good candidates by visual inspection of the peaks.
Finally, 3 of the newly validated target genes (FLJ45422, TPP1 and
MYBPC2) were again not singled out as likely candidates. In
conclusion, neither alternative approach was superior to our original
method with respect to specificity or sensitivity. More importantly,
the alternative methods did not identify a large number of likely
targets that were missed by our original procedure.
Binding of CIITA to the New Targets in DC and IFNc
Induced Cells
Strong and reproducible peaks were also evident at the new
target genes in ChIP-chip experiments comparing ChIP probes
from iDC and mDC (Figure 4A, Table 1). We therefore performed
quantitative ChIP experiments to measure binding of CIITA to
the new targets in iDC. For eight of the new targets, significant
binding was observed in iDC (Figure 4B). As observed for the
control HLA-DRA and Ii genes, this binding was strongly reduced
in mDC (Figure 4B).
CIITA can be induced in most CIITA negative cells by
stimulation with IFNc (Figure 1A). We therefore performed
quantitative ChIP experiments to determine whether binding of
CIITA to the new targets is induced by IFNc in a melanoma cell
line exhibiting well documented IFNc induced CIITA expression
[35]. IFNc induced occupation by CIITA was evident at all nine
new target genes (Figure 4C). As observed for the control HLA-
DRA and Ii genes, this occupation by CIITA is induced rapidly,
reaching maximal levels by 6 hours of stimulation (Figure 4C).
Recruitment of CIITA to the New Targets Is Dependent
on RFX
At all nine new target genes, strong and reproducible peaks
were evident in ChIP-chip experiments comparing CIITA-ChIP
probes from Raji and SJO cells (Figure 5A, Table 1). This
suggested that recruitment of CIITA to the new genes is – as
established for other known target genes – strictly dependent on
binding of RFX. To verify this we performed quantitative ChIP
experiments comparing binding of CIITA between Raji, RFX5-
deficient SJO cells and RFXANK-deficient BLS1 cells. As
observed for the control HLA-DRA and Ii genes, binding of
CIITA is completely lost in SJO and BLS1 cells, indicating that it
requires an intact RFX complex (Figure 5B).
To document binding of RFX to the new target genes directly, we
performed quantitative ChIP experiments with Raji, RJ2.2.5 and
SJO cells. As shown previously for well established CIITA regulated
genes [30,31], binding of RFX to the new target genes is strong in
Raji, unaffected in RJ2.2.5, but completely abolished in SJO
(Figure 5C). Finally, RFX was also found to bind to the new target
genes in iDC (Figure 5D) and IFNc induced cells (data not shown).
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The analysis of RFX5, RFXAP and RFXANK mRNA abundance
by quantitative RT-PCR demonstrated that the level of RFX
expression is very similar in Raji B cells and iDC (data not shown).
This is consistent with the observation that the strength of CIITA
binding observed in ChIP-chip experiments at validated target
genes is very similar between Raji and DC (compare Figures 3B
and 4A).
CIITA Is Recruited to the New Targets via a Typical S-Y
Enhancer
The finding that recruitment of CIITA to the new target genes
is dependent on binding of RFX prompted us to search for
sequences resembling the S-Y enhancer. In all MHC-II genes, the
S, X, X2 and Y boxes of the S-Y enhancer are highly conserved
with respect to their order, orientation and spacing (Figure 6A) [7–
9]. A similar tightly-constrained arrangement of S, X, X2 and Y
sequences was evident in six of the new target genes (RAB4B,
FLJ45422, ZNF672, MYBPC2, TPP1 and PSMD3) at positions
lying within the region to which CIITA is recruited (Figure 6A).
Homology to a complete S-Y motif was less evident in the
remaining three new target genes (TRIM26, KIAA0841 and RFX5).
Although these three genes do contain a well conserved X/X2
region, no obvious S element is evident and only two of them
(TRIM26 and RFX5) have a Y-like sequence (Figure 6A). This
prompted us to determine whether NF-Y actually binds to the new
S-Y enhancers. Quantitative ChIP experiments performed with an
NF-Y antibody confirmed that the new S-Y enhancers, including
two of the imperfect ones, are indeed bound by NF-Y (Figure S3).
The only gene to which binding of NF-Y was detected only very
weakly is the one (KIAA0841) lacking a potential Y-like sequence.
To determine whether the new S-Y motifs can function as RFX
and CIITA dependent enhancers we generated reporter gene
constructs in which the S-Y motif of the HLA-DRA promoter was
replaced with the S-Y motifs from the new target genes (Figure 6A).
The activity of these chimeric constructs, the control HLA-DRA
construct and a construct driven by a minimal promoter lacking
an S-Y module were assessed in Raji, RJ2.2.5 and SJO cells
(Figure 6B). In Raji, the constructs containing the new S-Y motifs
exhibited activities that were at least 20-fold greater than the basal
activity of the minimal promoter and attained levels ranging from
25% to 40% of the activity of the HLA-DRA construct. This
expression was abolished in RJ2.2.5 and SJO cells. These results
confirm that the new S-Y motifs function as transcriptional
enhancers regulated by RFX and CIITA. To confirm that the X
box is a critical element of the new S-Y enhancers we performed
reporter gene assays with constructs having a mutated X box
(Figure 6C). The X box mutation strongly decreased activity of the
new S-Y enhancers (Figure 6C). We have recently reported similar
results for the new S-Y motif of RAB4B [32].
Regulation of the New Target Genes by CIITA
To confirm that the novel target genes are regulated by CIITA
we quantified their endogenous mRNA abundance by quantitative
RT-PCR in RJ2.2.5 cells and in RJ2.2.5 cells complemented with
a CIITA expression vector (Figure 7A). Expression of eight of the
new target genes (RAB4B, TRIM26, FLJ45422, KIAA0841, RFX5,
ZNF672,MYBPC2 and TPP1) was significantly reduced in RJ2.2.5.
This reduction was not as strong as that observed for classical
targets of CIITA, such as HLA-DRA. However, it was similar to or
stronger than the reduction observed for HLA-C. The new targets
thus resemble MHC-I genes in that their expression is modulated
by, but not strictly dependent on, CIITA [7–11].
We next performed real-time RT-PCR experiments with
melanoma cells to determine whether expression of the new
target genes is induced by IFNc (Figure 7B). mRNA abundance
for four of the new target genes (RAB4B, FLJ45422, MYBPC2 and
RFX5) was increased by IFNc according to a time course similar to
that observed for the control HLA-DRA and HLA-C genes.
Although induction of the new target genes was not as strong as
for HLA-DRA, it was similar in magnitude to the induction of HLA-
C. The new targets thus behave like MHC-I genes in that they
exhibit a significant level of basal expression prior to IFNc induced
CIITA expression [7–12].
Discussion
We have used four ChIP-chip approaches to establish a list of
genes regulated directly by CIITA in B cells and DC. In addition
to MHC-II, MHC-I and Ii genes, only nine new bona fide target
genes were discovered. The current number of genes that have
been demonstrated to be regulated directly by binding of CIITA
does therefore not exceed twenty five. At all of these genes, the
recruitment of CIITA is strictly dependent on binding of RFX to
an X box sequence situated near the promoter. In most cases, this
X box is situated in a characteristic S-Y enhancer. One of the new
target genes encodes the RFX5 subunit of RFX, indicating the
existence of a positive feedback loop for enhancing CIITA
recruitment. Finally, seven of the nine new target genes are
known or likely to be implicated in cellular processes contributing
to antigen presentation (see below). Taken together, these results
show that CIITA is dedicated for the regulation of a remarkably
compact and highly specialized gene expression module devoted to
antigen presentation. This is consistent with the fact that all
phenotypes documented in BLS patients can be attributed to
defects in antigen presentation. Furthermore, the finding that
CIITA recruitment is strictly dependent on RFX at all validated
target genes is in agreement with the observation CIITA deficient
patients can not be distinguished phenotypically from RFX-
deficient patients.
Robust and reproducible binding of CIITA was observed at all
previously known and newly validated target genes in nine
independent ChIP-chip experiments. No other bona fide target
genes were identified by any of the four strategies. Genes at which
signals were weaker and less reproducible turned out to be false
positives. This suggests that most target genes of CIITA have been
identified. It is nevertheless possible that certain target genes have
been missed. There could be additional targets in specific cell
Figure 3. Identification of novel target genes of CIITA. (A) Binding of CIITA to the indicated genes was assessed in Raji B cells by quantitative
ChIP. The HLA-DRA and Ii genes were used as positive controls. As negative control we used a sequence exhibiting only nonspecific CIITA association
(background). Scores assigned to the candidate target genes (see Materials and Methods, Tables S1 and S2) are indicated above. Results are
expressed relative to binding of CIITA at HLA-DRA, and show the mean and SD of 3 independent experiments (each performed with triplicate PCR
measurements). Binding was deemed significant if it was greater than 2-fold above background. (B) Representative CIITA-binding profiles obtained in
ChIP-chip experiments are provided for the nine new target genes validated in panel A. Results are represented as in Figure 2 for ChIP-chip
experiments comparing Raji and RJ2.2.5 cells. (C) Binding of CIITA to the new target genes was confirmed by quantitative ChIP experiments
performed with Raji and RJ2.2.5 cells. Positive (HLA-DRA, Ii) and negative (background) controls were as in panel A. Results are expressed relative to
binding of CIITA at HLA-DRA in Raji, and show the mean and SD of 3 independent experiments (each performed with triplicate PCR measurements).
doi:10.1371/journal.pgen.1000058.g003
Remarkably Tight CIITA Target Gene Specificity
PLoS Genetics | www.plosgenetics.org 8 April 2008 | Volume 4 | Issue 4 | e1000058
Figure 4. CIITA binds to the new target genes in DC and IFNc induced cells. (A) Representative CIITA-binding profiles obtained for the new
target genes in ChIP-chip experiments performed with DC. Results are represented as in Figure 2 for ChIP-chip experiments comparing iDC and mDC.
(B) Binding of CIITA to the new target genes was confirmed by quantitative ChIP experiments performed with iDC and mDC. Results are expressed
relative to binding of CIITA at HLA-DRA in iDC, and show the mean and SD of 3 independent experiments (each performed with triplicate PCR
measurements). (C) Binding of CIITA to the new target genes was confirmed by quantitative ChIP experiments performed with Me67.8 melanoma
cells stimulated for 0, 6 or 12 hours with IFNc. Results are expressed relative to the plateau level obtained at HLA-DRA in cells induced for 12 hours,
and show the mean and SD of 3 independent experiments (each performed with triplicate PCR measurements). Positive (HLA-DRA, Ii) and negative
(background) controls were as in Figure 3.
doi:10.1371/journal.pgen.1000058.g004
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types. In this respect it may be relevant that the COL1A2 promoter
was not found to be occupied by CIITA in B cells or DC (Figure
S4 and Figure S5) although earlier ChIP experiments had
suggested that CIITA regulates this gene in IFNc induced cells
[22]. It is also possible that certain targets were missed for
technical reasons. For example, the relevant CIITA associated
sequences could be refractory to PCR amplification, hybridize
inefficiently or have been excluded by the NimbleGen array design
program. Finally, additional target genes could be controlled by
distant CIITA-dependent enhancers that are situated outside of
the 5 kb promoter regions present on the NimbleGen arrays. To
address the latter possibility we performed ChIP-chip experiments
Figure 5. Recruitment of CIITA to the new target genes is dependent on binding of RFX. (A) Representative CIITA binding profiles
obtained for the new target genes in ChIP-chip experiments comparing Raji and SJO cells. Results are represented as in Figure 2. (B) Binding of CIITA
to the new target genes was assessed by quantitative ChIP experiments performed with Raji, SJO and BLS1 cells. Results are expressed relative to
binding of CIITA at HLA-DRA in Raji, and show the mean and SD of 3 independent experiments (each performed with triplicate PCR measurements).
(C) Binding of RFX to the new target genes was assessed by quantitative ChIP experiments performed with Raji, RJ2.2.5 and SJO cells. Results are
expressed relative to binding of RFX at HLA-DRA in Raji, and show the mean and SD of 3 independent experiments (each performed with triplicate
PCR measurements). (D) Binding of RFX to the new target genes was assessed by quantitative ChIP experiments performed with iDC. Results are
expressed relative to binding of RFX at HLA-DRA, and show the mean and SD of 3 independent experiments (each performed with triplicate PCR
measurements). nd, not done.
doi:10.1371/journal.pgen.1000058.g005
Figure 6. The new target genes contain RFX and CIITA dependent S-Y enhancers. (A) Alignment between the S-Y motif of the HLA-DRA
gene and sequences found within the regions to which CIITA is recruited at the new target genes. Sequences corresponding to the S, X, X2 and Y
elements are boxed. The dashed box indicates a pyrimidine (py) rich region generally found at the 59 end of the X box. Numbers indicate spacing in
nucleotides between the S and py or X2 and Y sequences. S and Y sequences are only shown if homology is evident. (B) Transient transfections were
performed with luciferase reporter gene constructs containing the HLA-DRA regulatory region or hybrid promoters in which the S-Y motif of HLA-DRA
was replaced with the S-Y sequences from the indicated new target genes. A construct containing the basal HLA-DRA promoter lacking the S-Y
module (min) was used as negative control. Constructs were transfected into Raji, RJ2.2.5 and SJO cells. Results are expressed relative to the activity of
the HLA-DRA construct in Raji, and show the mean and SD of 3 independent experiments (each performed with triplicate luciferase measurements).
(C) A mutation disrupting the X box was introduced into the constructs containing the new S-Y enhancers. Activities of the wild type (wt) and
mutated (Xm) constructs were compared in Raji cells. Results are expressed relative to the activity of wt construct, and show the mean and SD of 3
independent experiments (each performed with triplicate luciferase measurements).
doi:10.1371/journal.pgen.1000058.g006
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using a high density array of our own design carrying the entire
extended human MHC as well as other selected regions of interest,
including several of the target genes identified here (see Materials
and Methods). ChIP-chip experiments performed with Raji and
DC confirmed binding of CIITA to all target genes present on the
array but did not - with the exception of known enhancers found
in the vicinity of MHC-II genes [36,37] - lead to the identification
of any novel intergenic binding sites (Table S2, Figure S6). This
contrasts with the high density of STAT1, p53 and NF-kB binding
sites found by ChIP-chip in chromosome 22, many of which are
situated far from transcription start sites. Intergenic CIITA-
binding sites do thus not appear to be frequent, although we can of
course not exclude their existence in other regions of the genome.
The functions of two of the new target genes are unknown.
KIAA0841 encodes a protein containing no characteristic sequence
motifs providing clues to its function. ZNF672 encodes a
transcription factor belonging to the Kreuppel zinc-finger family
[38]. However, the genes and functions that ZNF672 might
regulate are unknown. For the remaining seven new target genes
there is a known or potential link within antigen presentation by
MHC-II or MHC-I molecules. TRIM26 and FLJ45422 are
situated with the class I region of the MHC. For RAB4B and
RFX5, a key role in antigen presentation has already been
established. RFX5 plays a pivotal role in activating MHC-II
expression because it encodes the largest DNA-binding subunit of
RFX and is essential for recruiting CIITA to its target genes [30–
33]. RAB4B encodes an isoform of the small GTPase RAB4.
RAB4 is associated with early and recycling endosomes, and
regulates recycling of membranes and proteins from these
compartments back to the cell surface [39]. These recycling
processes play important roles in various antigen presentation
processes, including MHC-II restricted presentation of peptides
derived from antigens internalized by receptor-mediated uptake in
B cells, cross-presentation of endocytosed antigens by MHC-I
molecules in DC and the presentation of intact proteins by DC to
the antigen receptors of B cells [40–44]. RAB4 has been
implicated directly in the MHC-II restricted presentation of
antigens internalized by receptor-mediated uptake in B cells [44].
Figure 7. The new target genes are regulated by CIITA in B cells and are induced by IFNc. (A) mRNA levels for the new target genes were
compared between RJ2.2.5 cells (open bars) and RJ2.2.5 cells complemented with a CIITA expression vector (black bars). Results are represented
relative to the expression found in the complemented cells, and show the mean and SD of 3 independent experiments (each performed in triplicate
PCR measurements). (B) mRNA levels for the indicated target genes were measured in Me67.8 cells induced with IFNc for 0, 12, 24 and 48 hours.
Results are represented as fold induction relative to uninduced cells, and show the mean and SD of 3 independent experiments (each performed in
triplicate PCR measurements). HLA-DRA and HLA-C were included as control CIITA-regulated genes.
doi:10.1371/journal.pgen.1000058.g007
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For MYBPC2, TRIM26, PSMD3, TPP1 and FLJ45422, a role in
antigen presentation is suggested by the nature of the protein and/
or the cellular processes in which they function. FLJ45422 encodes
a protein of unknown function exhibiting similarity to MHC-I
molecules. TPP1 encodes a lysosomal protease [45] that could
influence the generation of peptides presented by MHC-II
molecules. PSMD3 encodes a regulatory subunit of the protea-
some, a large protease complex implicated in the generation of
peptides presented by MHC-I molecules [46]. MYBPC2 encodes
an immunoglobulin superfamily member [47] that can bind to
myosin and filamentous actin, and modifies the actin-stimulated
ATPase activity of myosin. Although MYBPC2 is expressed
abundantly in muscle and is best known for its role in muscle
contraction [48], it is also expressed at lower level in other cell
types and its tight regulation by CIITA suggests that it could have
additional functions in antigen presenting cells. Importantly, the
actin cytoskeleton and/or actin-based myosin motors have been
implicated in MHC-II trafficking and receptor-driven antigen
presentation in B cells, the formation of immune synapses between
antigen presenting cells and T cells, and antigen capture and
presentation by MHC-I and MHC-II molecules in DC [49–51].
Finally, TRIM26 encodes a member of the tripartite motif (TRIM)
family of ubiquitin E3 ligases [52]. Members of this family are
implicated in diverse biological processes. They promote the
ubiquitination of specific substrate proteins, thereby controlling
their abundance by proteasome mediated degradation or their
activity, intracellular trafficking or subcellular localization by
proteasome-independent mechanisms. It is tempting to speculate
that TRIM26 may regulate either the generation of specific
antigenic peptides by the proteasome, or the abundance, activity
or subcellular localization of specific proteins implicated in antigen
presentation.
The CIITA gene is frequently silenced by epigenetic mecha-
nisms in tumors. It has been proposed that the loss of MHC-II
expression and/or a reduction in MHC-I expression resulting
from the silencing of CIITA might allow tumors to evade immune
surveillance [23,53]. Our finding that CIITA is remarkably
specific for genes implicated in antigen presentation is consistent
with the hypothesis that the association between silencing of CIITA
and tumorigenicity reflects a reduction in the antigen presentation
capacity of the tumor cells. Although there is a well established link
between the loss of MHC-I expression and escape from immune
surveillance [54], it remains unclear how direct MHC-II mediated
antigen presentation by tumor cells contributes to anti-tumor
responses in vivo. Therefore, an alternative possibility that has to be
kept in mind is that defective CIITA expression could represent a
selective advantage for tumors because it contributes to the
expression of non-MHC genes. In this respect, certain of the new
target genes may be relevant. For instance, an altered transcription
program due to reduced ZNF672 expression, deregulated vesicular
traffic due to reduced RAB4B expression, perturbed intracellular
actin-based transport due to reduced MYBPC2 expression, and
altered ubiquitin-dependent degradation or regulation of specific
proteins due to lower TRIM26 expression, could all contribute to
the development of tumors.
Two of the new target genes, RAB4B and TPP1, had been
suggested to be regulated by CIITA in earlier studies. Both were
among the genes that were found by microarray experiments to be
downregulated in CIITA-deficient cells [14]. RAB4B was also
singled out by a bioinformatic screen designed to identify genes
containing S-Y motifs [32]. In contrast, more than 70 other genes
suggested previously to be regulated by CIITA [13–22] were not
found to be direct targets in our ChIP-chip experiments (Figure
S4). For several of the most interesting candidates we were
moreover unable to confirm binding of CIITA to their promoters
by classical ChIP experiments (Figure S5). Finally, in a previous
study using CIITA-deficient and CIITA-transgenic mice no direct
control of these genes by CIITA could be documented [55]. The
influence of CIITA on the expression of these genes is therefore
likely to be mediated by indirect mechanisms. For several genes,
an indirect mechanism involving sequestration of the general co-
activator CBP by CIITA has been proposed [16,17,21]. Certain of
the genes could be regulated by one of the two transcription
factors - RFX5 and ZNF672 - shown here to be controlled by
CIITA. Finally, there is growing evidence that ubiquitination and
regulatory subunits of the proteasome can play key roles in
transcriptional regulation [56]. The modulation of TRIM26 and
PSMD3 expression by CIITA could thus have indirect impacts on
the transcription of certain genes.
The remarkably focused role of CIITA emphasized here
contrasts with results derived from large-scale binding studies for
other transcription factors. Good illustrations are provided by
Foxp3, Stat1, cMyc and p53. Over 1000 Foxp3 target genes were
identified by scanning for binding sites in the promoter regions of
16’000 mouse genes [1]. Large scale mapping of Stat1 binding
sites in chromosome 22 or selected (ENCODE) regions of the
human genome have pointed to hundreds if not thousands of
target genes [2,3]. More than 300 cMyc target sites were identified
in chromosomes 21 and 22 [4]. Finally, p53 binds to at least 500
target sites in the human genome [5]. Similar large numbers of
targets have been reported for all other transcription factors for
which large-scale binding studies have been reported. The high
degree of specificity observed here for CIITA is thus unprecedented.
Why CIITA presents this unique degree of specificity is unknown.
One explanation may reside in the finding that CIITA recruitment
appears to be strictly dependent on the assembly of a well-defined
multifactor enhanceosome complex on a relatively large (65–70 bp)
composite regulatory module (the S-Y motif) that is tightly
constrained with respect to its sequence content and architecture
[32]. Such S-Y modules are likely to be much less frequent in the
genome than binding sites for individual transcription factors. A
second explanation may lie in the fact that CIITA has quite an
unusual origin for a nuclear transcription factor. It is the only
transcriptional activator belonging to the mammalian nucleotide-
binding domain and leucine-rich repeat (NLR) containing family, a
large group of proteins exerting cytoplasmic functions implicated in
cell death, inflammation and innate immunity [57–59]. The ability
to activate transcription of a specific set of genes in the adaptive
immune system may represent a recently evolved specialization
acquired by an ancestral NLR protein originally having a completely
different cytoplasmic function.
Materials and Methods
Cells
Raji, BLS1, SJO and RJ2.2.5 B cells, RJ2.2.5 cells comple-
mented with an expression vector encoding CIITA isoform III
[32] and Me67.8 melanoma cells [35] were cultured in RPMI +
Glutamax medium complemented with 10% fetal calf serum and
antibiotics. Me67.8 cells were induced with 200U/ml IFNc
(Invitrogen). Human monocyte-derived DC were generated and
matured with LPS as described [24].
Chromatin Immunoprecipitation (ChIP)
ChIP experiments were performed as described using antibodies
specific for CIITA and RFX [30,31] or NF-Y (Diagenode). Results
were quantified by real-time PCR using the primers listed in Table
S3. PCR was performed using the iCycler iQ Real-Time PCR
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Detection System (Biorad) and a Sybr-Green-based kit for
quantitative PCR (iQ Supermix Biorad).
ChIP-Chip Experiments
CIITA-ChIP samples were verified by quantitative PCR to
assess the enrichment of HLA-DRA sequences. DNA extracted
from the ChIP samples were blunted for 30 minutes at 72uC with
3U of Pfu polymerase (Promega) and phosphorylated with T4
Polynucleotide kinase (New England Biolabs). 120 pmoles of
adaptors, consisting of annealed oligonucleotides A (59-
GCGGTGACCCGGGAGATCTGAATTC-39) and B (59-
GAATTCAGATC-39), were ligated to the DNA by overnight
incubation at 16uC with 2000U of T4 DNA ligase (New England
Biolabs). Two rounds of PCR amplification with oligonucleotide A
were performed using 1.25U of Taq polymerase (New England
Biolabs) and 0.025U of PfuTurbo polymerase (Stratagene). The
cycle used was: 1 X (29 at 55uC, 59 at 72uC, 29 at 95uC), 28 X (19
at 95uC, 19 at 60uC, 29 at 72uC), 59 at 72uC. 4 mg of each DNA
were purified and sent to NimbleGen for probe preparation and
hybridization to arrays carrying the 5 kb promoter regions
(approximately 24 kb to +1 kb relative to the transcription start
site) of 27434 human genes, or to a custom array of our own
design. The latter carries all unique sequences from the entire
extended human MHC (7.7 Mb on chromosome 6, genomic
coordinates 26.1 Mb to 33.8 Mb on hg17) as well as a number of
other selected regions (total of 0.9 Mb), including several of the
target genes identified here. These genomic regions are covered at
high density with overlapping Tm-matched oligonucleotides (,50
bp long) spaced such that their 59 ends are situated ,10 bp apart.
Analysis of ChIP-Chip Data
Data sets from five independent experiments (three Raji/
RJ2.2.5 and two iDC/mDC comparisons) were analyzed with
SignalMap software (NimbleGen). Positive peaks in the test/
control signal ratios were calculated using a 500 base-pair sliding
window and a cut-off that was deliberately set at a very low value
(5% of maximum) to minimize the risk of eliminating weak peaks.
This generated a large number of potential peaks (11262, 13322
and 15980 in the three Raji/RJ2.2.5 experiments, 13017 and
11795 in the two iDC/mDC experiments. The following
procedure was then used to identify peaks present reproducibly
in the five experiments. First, all peaks found in the five
experiments were merged into a single list and sorted according
to their genomic midpoint coordinates. A sliding window of five
consecutive peaks was then used to identify genes exhibiting a peak
in each of the five experiments. For these genes, the distance was
calculated between the midpoints of the first and fifth peak and the
list of these genes was then resorted according to these calculated
peak proximities. Since the likelihood that peaks detected in
different experiments correspond to the same binding site will
increase with increased peak proximity, candidates with the
smallest distance values between peaks were considered to be the
most likely candidates. Similar algorithms were used to identify
peaks present in only four or three of the five experiments. Finally,
to avoid the risk of eliminating target genes because of a threshold
difference between B cells and DC, all genes exhibiting closely
superposable peaks in only the three Raji/RJ2.2.5 experiments or
only the two iDC/mDC experiments were retained as candidates.
Peaks for approximately 500 candidate genes identified by this
procedure were re-examined visually and assigned a score based
on reproducibility, width and strength of the signals. A score of 3
was assigned to genes where strong signals (log2 ratios exceeding 2)
were spread over at least 400 base-pairs and were present in at
least four experiments. A score of 2 was assigned to genes where
strong signals were present in at least three experiments, or when
weaker or narrower peaks were present in four or five experiments.
A score of 1 was assigned to genes where three experiments
exhibited weak signals or when signals were detected in only two
experiments. A score of 0 was assigned to genes that did not meet
the above criteria. To simplify representation of the results in the
Figures, negative test/control signal ratios were set at log2 = 0.
Two alternative approaches were also used to analyze the ChIP-
chip data. One was a published method [34]. The second
consisted of the following unsupervised approach. Peaks from the
three Raji/RJ2.2.5 and two iDC/mDC experiments were pooled
together, sorted by chromosome, midpoint coordinate and
experiment, and considered to correspond to the same binding
site if their distance was , 750 bp. Peaks that were only positive in
1 or 2 experiments were excluded from the following steps. To
identify groups in the remaining peaks, they were represented as 4
bit binary vectors with the first 2 bits representing the number of
peaks with significant log2 ratios and the last 2 bits representing the
number of positive experiments. Log2 ratios were considered
significant if their values were above 0.66, which corresponds to
the quantile for a probability of 0.95 calculated on the complete set
of log2 ratios determined over all experiments and peaks. Since the
binary variables are asymmetric, a distance matrix between any
pair of peaks represented by the rows of the binary matrix is
calculated using the Jaccard distance [60]. This distance measure
ranges from 0 (closely related peaks) to 1 (unrelated peaks). The
resulting distance matrix was then used to determine the number
of groups (partitions) using the PAM (Partitioning Around
Medoids) algorithm [61]. Based on the above distance matrix,
this algorithm calculates all possible partitions ranging from 2 to n-
1 subgroups. For each partition the overall average silhouette
width [62] is calculated and the partition that maximizes it is
considered optimal.
Plasmids and Reporter Gene Assays
S-Y motifs were amplified by PCR and cloned in the HLA-DRA
luciferase plasmid described previously [31]. The X box was
altered to AAGCTACCACTCGT by site directed mutagenesis as
described [32]. This mutation has a major impact on the activity
of known S-Y enhancers. Transfections were done by electropo-
ration. Dual luciferase reporter gene assays were performed
according to instructions from the manufacturer (Promega).
mRNA Quantification
RNA extraction and cDNA synthesis were done as described
[31]. Quantification was done by real-time PCR using the primers
listed in Table S4. Results were normalized using 18S rRNA.
Results were confirmed with several primer pairs.
Supporting Information
Figure S1 CIITA binding profiles are shown for three well known
target genes, HLA-DRA (left column), HLA-DRB1 (middle column)
and HLA-DMA (right column). The ChIP-chip profiles are derived
from three Raji/RJ2.2.5, one Raji/input, three Raji/SJO and two
iDC/mDC experiments. Results are represented as log2 ratios
between the hybridization signals obtained with the test probes
(CIITA-ChIP samples from Raji or iDC) and the control probes
(input DNA or CIITA-ChIP samples from RJ2.2.5, SJO or mDC).
Each dot corresponds to a single oligonucleotide on the array. The
dotted lines in the HLA-DRA profile of the Raji/input experiment
and theHLA-DMA profile of the third Raji/SJO experiment indicate
sporadic peaks probably representing LM-PCR amplification
artifacts. The schematic maps above the profiles show positions of
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the transcription start sites (arrows) and S-Y enhancers (grey boxes).
The scale in Kb relative to the transcription start site is provided
below.
Found at: doi:10.1371/journal.pgen.1000058.s001 (0.52 MB PDF)
Figure S2 ChIP-chip results are shown for six control genes
(GAPDH, ACTB, PTPRC, CD19, ITGAX, and LY75) that are not
regulated by CIITA. Representative profiles from Raji/RJ2.2.5
(left column), iDC/mDC (middle column) and Raji/SJO (right
column) experiments are shown. Results are represented as log2
ratios between the hybridization signals obtained with the test
probes (CIITA-ChIP samples from Raji or iDC) and the control
probes (CIITA-ChIP samples from RJ2.2.5, mDC or SJO). Each
dot corresponds to a single oligonucleotide on the array. The
dotted lines in the iDC/mDC profiles shown for ACTB and LY75
indicate sporadic peaks probably representing LM-PCR amplifi-
cation artifacts. The scale in Kb relative to the transcription start
site is provided below.
Found at: doi:10.1371/journal.pgen.1000058.s002 (0.40 MB PDF)
Figure S3 Binding of NF-Y to the indicated new target genes
was assessed by quantitative ChIP experiments performed with
Raji cells. Results are expressed relative to binding of NF-Y at
HLA-DRA. As negative control we used a sequence exhibiting only
nonspecific CIITA association (background). Results show the
mean and SD of 2 independent experiments (each performed with
triplicate PCR measurements).
Found at: doi:10.1371/journal.pgen.1000058.s003 (0.01 MB PDF)
Figure S4 ChIP-chip results are shown for eight genes (COL1A2,
EIF3I, FASLG, IL4, KPNA6, RBBP4, YARS, and PLXNA1)
previously suggested to be regulated by CIITA. Representative
profiles from Raji/RJ2.2.5 (left column), iDC/mDC (middle
column) and Raji/SJO (right column) experiments are shown.
Results are represented as log2 ratios between the hybridization
signals obtained with the test probes (CIITA-ChIP samples from
Raji or iDC) and the control probes (CIITA-ChIP samples from
RJ2.2.5, mDC or SJO). Each dot corresponds to a single
oligonucleotide on the array. The scale in Kb relative to the
transcription start site is provided below.
Found at: doi:10.1371/journal.pgen.1000058.s004 (0.42 MB PDF)
Figure S5 Binding of CIITA to the IL4, FASLG, KPNA6, YARS,
EIF31, PLXNA1, RBBP4, and COL1A2, genes was assessed by
quantitative ChIP experiments performed with Raji (R) and
RJ2.2.5 (RJ) cells. Results are expressed relative to binding of
CIITA at HLA-DRA in Raji. As negative control we used a
sequence exhibiting only nonspecific CIITA association (back-
ground). Two different COL1A2 primer pairs were tested. Results
show the mean of triplicate PCR measurements obtained for a
representative experiment.
Found at: doi:10.1371/journal.pgen.1000058.s005 (0.01 MB PDF)
Figure S6 CIITA-ChIP-chip experiments performed with a
high density custom array. (A) Representative CIITA binding
profiles are shown for HLA-DRA, HLA-DMA, FLJ45422, and
TRIM26 (top four profiles) and for candidate distant sequences A
and B (bottom two profiles). Results are represented as log2 ratios
between the hybridization signals obtained with CIITA-ChIP
samples from Raji and RJ2.2.5. The scale in Kb relative to the
transcription start site (arrows) is provided for the four genes. For
the potential distant binding sites the nucleotide coordinates on
chromosome 6 are indicated. (B) Binding of CIITA to the HLA-
DRA gene and to the two potential binding sites A and B were
assessed by quantitative ChIP experiments performed with Raji
(R) and RJ2.2.5 (RJ) cells. Results are expressed relative to binding
of CIITA at HLA-DRA in Raji. As negative control we used a
sequence exhibiting only nonspecific CIITA association (back-
ground).
Found at: doi:10.1371/journal.pgen.1000058.s006 (0.05 MB PDF)
Table S1 Score 1 genes identified by CIITA-ChIP-chip
experiments.
Found at: doi:10.1371/journal.pgen.1000058.s007 (0.09 MB PDF)
Table S2 ChIP-chip experiments performed with a custom
high-density MHC array.
Found at: doi:10.1371/journal.pgen.1000058.s008 (0.10 MB PDF)
Table S3 Primer sequences used for ChIP.
Found at: doi:10.1371/journal.pgen.1000058.s009 (0.01 MB PDF)
Table S4 Primer sequences used for real-time RT-PCR.
Found at: doi:10.1371/journal.pgen.1000058.s010 (0.08 MB PDF)
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